RNXT — RenovoRx Inc
NASDAQ · Healthcare · Biotechnology
$2.11
+$0.18 (+9.33%)
RenovoRx Inc (RNXT) is a biotechnology company listed on NASDAQ. It is led by Shaun R. Bagai, based in 2570 West El Camino Real, Mountain View, CA, United States, 94040, with about 10 employees. RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Latest reported RNXT revenue for 2025-09-30 was $266.0K. Net income was -$2.9M. Revenue was down 37.0% from 2025-06-30 to 2025-09-30. RNXT currently screens at market cap $47.0M.
Use this RNXT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RNXT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RNXT SEC filings page. Lician reads the product cache first so this HTML stays unique to RenovoRx Inc even when a live quote feed is slow.
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
RNXT Key Statistics
Market Cap
$47.00M
Volume
1.27M
Previous Close
$1.25
Day Range
$1.27 – $1.56
EPS
-$0.40
Revenue
$43.00K
Net Income
-$8.81M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-20497.7%
Employees
10
RNXT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $43.00K | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.81M | -$10.23M | -$9.89M | -$6.32M |
| EPS (Diluted) | -$0.40 | -$0.99 | -$1.09 | $0.00 |
Total Assets
$8.12M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$7.15M
Operating Cash Flow
-$9.13M
Free Cash Flow
$0.00
RenovoRx Inc Company Information
- CEO, Secretary & Director
- Shaun R. Bagai
- Headquarters
- 2570 West El Camino Real, Mountain View, CA, United States, 94040
- Website
- renovorx.com
- Phone
- 650 284 4433
- IPO / Founded
- 2021-08-26
- Sector
- Healthcare
- Industry
- Biotechnology